Compare Agilent Technologies Inc (A) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Invesco Ltd. — how do they compare? Agilent Technologies Inc trades at $128.99 (market cap $37.04B), while Invesco Ltd. trades at $27.02 (market cap $12.15B). The key difference: Agilent Technologies Inc is far larger — about 3× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| A | IVZ | |
|---|---|---|
Market Cap | $37.04B | $12.15B |
Sector | Health | Financials |
52-Week High | $157.20 | $29.44 |
52-Week Low | $110.24 | $16.69 |
Enterprise Value | $38.59B | $22.39B |
Dividend Yield | 0.78% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Invesco (IVZ) trades at $27.40, up 1.44% today, with a bullish technical signal from moving averages and support at $27. The company reported mixed Q1 2026 earnings, missing estimates, but has beaten expectations in two prior quarters. Revenue grew to $6.38B in 2025, though net income was negative at -$281.70M. Operating cash flow remains strong at $1.53B, and a dividend of $0.22 is scheduled for June 2026.
Outlook: Analyst consensus is mixed with 43% buy ratings and a $29.44 price target, suggesting modest upside. Risks include persistent negative profitability and competitive pressures in asset management. The stock offers value with a P/E of 19.48 but requires monitoring of earnings turnaround and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
